SynCore Biotechnology Co Ltd - Asset Resilience Ratio
SynCore Biotechnology Co Ltd (4192) has an Asset Resilience Ratio of 2.58% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is SynCore Biotechnology Co Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how SynCore Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 4192 asset base.
Liquid Assets Composition Over Time
This chart breaks down SynCore Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 4192 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$7.04 Million | 2.58% |
| Total Liquid Assets | NT$7.04 Million | 2.58% |
Asset Resilience Insights
- Limited Liquidity: SynCore Biotechnology Co Ltd maintains only 2.58% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SynCore Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare SynCore Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for SynCore Biotechnology Co Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for SynCore Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.19% | NT$6.96 Million ≈ $219.15K |
NT$317.80 Million ≈ $10.01 Million |
+0.43pp |
| 2023-12-31 | 1.76% | NT$6.66 Million ≈ $209.83K |
NT$378.36 Million ≈ $11.92 Million |
+0.23pp |
| 2022-12-31 | 1.53% | NT$6.66 Million ≈ $209.83K |
NT$436.65 Million ≈ $13.76 Million |
+0.72pp |
| 2021-12-31 | 0.81% | NT$6.66 Million ≈ $209.83K |
NT$824.44 Million ≈ $25.97 Million |
+0.08pp |
| 2020-12-31 | 0.73% | NT$6.66 Million ≈ $209.83K |
NT$913.99 Million ≈ $28.80 Million |
-0.14pp |
| 2019-12-31 | 0.87% | NT$6.66 Million ≈ $209.83K |
NT$763.88 Million ≈ $24.07 Million |
+0.04pp |
| 2018-12-31 | 0.83% | NT$6.66 Million ≈ $209.83K |
NT$804.80 Million ≈ $25.36 Million |
+0.04pp |
| 2017-12-31 | 0.79% | NT$6.66 Million ≈ $209.83K |
NT$845.89 Million ≈ $26.65 Million |
+0.19pp |
| 2016-12-31 | 0.60% | NT$6.66 Million ≈ $209.83K |
NT$1.11 Billion ≈ $35.12 Million |
-0.05pp |
| 2015-12-31 | 0.65% | NT$6.63 Million ≈ $208.82K |
NT$1.03 Billion ≈ $32.36 Million |
-- |
About SynCore Biotechnology Co Ltd
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the trea… Read more